Michael Makris: How Haemophilia Care Is Delivered in China
Michael Makris, Emeritus Professor of Haemostasis and Thrombosis at University of Sheffield, reposted from RPTH Journal on LinkedIn:
”If you would like to know how haemophilia care is delivered in China then have a look at this paper.”
Quoting RPTH Journal‘s post about a recent article by Yun Wang et al, adding:
”Inherited bleeding disorders in China: a rapidly evolving therapeutic and healthcare landscape
With over 1.4 billion people, China faces a growing demand for the diagnosis and treatment of inherited bleeding disorders (IBDs), particularly haemophilia.
A new review in RPTH Journal takes stock of the remarkable progress made in recent years and the road ahead.
Key highlights:
- China is rapidly expanding its domestic manufacturing capacity for IBD therapeutics, from basic replacement therapies to advanced treatments including gene therapy
- A tiered healthcare system for haemophilia is being developed to optimise resource allocation and standardise care across both rural and urban areas
- A diverse pipeline of investigational domestic novel drugs is under active development
- The goal: more efficient, cost-effective, and accessible care for patients nationwide
This review offers a comprehensive overview of where China stands today, and where it is headed, in the management of inherited bleeding disorders.
The combination of domestic drug innovation and an evolving healthcare delivery system could significantly improve outcomes and quality of life for patients across the country.”
Title: The therapeutic landscape of inherited bleeding disorders in China
Authors: Yun Wang, Feng Xue, Man-Chiu Poon, Renchi Yang
Stay updated on all scientific advances with Hemostasis Today.
-
Jul 20, 2026, 13:18Ekaterina Balaian: Submission Open for Special Issue on Hematologic Metabolism
-
Jul 20, 2026, 12:54Victor Emmanuel: Preventing Severe Maternal Complications Associated With Anemia
-
Jul 20, 2026, 12:33Ney Carter Borges: The Evolving Role of Aspirin in Coronary Artery Disease
-
Jul 20, 2026, 12:15Zain Khalpey: Why the Cause of Reduced Perfusion Matters
-
Jul 20, 2026, 11:53ISTH 2026 Showcases Landmark Research and Launches Women’s Health Hub
-
Jul 20, 2026, 10:40Omid Seidizadeh: Advancing Genomic Insights into Bleeding Disorders at ISTH 2026
-
Jul 20, 2026, 10:30Marc Blondon: What Are the Current Practices For VTE Prevention in Pregnancy Worldwide?
-
Jul 20, 2026, 10:11Zeyad Bady: Advancing Thrombosis Research on the International Stage at ISTH 2026
-
Jul 20, 2026, 09:41Emily Bury: From Emerging Evidence to Better Patient Care at ISTH 2026